COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.
Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.
You may not be if
Participants in other clinical trials
patients with malignant tumors
pregnant and lactating women
co-infection with other infectious viruses or bacteria
History of several allergies
Patients with history of pulmonary embolism
any liver or kidney diseases
HIV positive patients
Considered by researchers to be not suitable to participate in this clinical trial
Chronic heart failure with ejection fraction less than 30%.
